Catalent Pharma Solutions has announced several expanded capabilities within its European Clinical Supply Services network. The expansions have been implemented in response to increased customer demand for specialty clinical packaging, where the proportion of highly-potent or temperature-sensitive investigational medical products continues to increase.
Legacy Pharmaceutical Packaging, in St. Louis, Missouri is proud of its entrepreneurial spirit,...
Catalent has appointed Thomas Castellano as Vice President Finance, Investor Relations, and...
Platinum Press a provider of healthcare packaging solutions for the pharmaceutical, medical device and animal care sectors specializing in labels, folding cartons, blister packaging, inserts/outserts and medication guides – is now a fully certified print packaging supplier for all Walgreens pharmacies.
Vetter Completes Structural Work on New Multi-Functional Development Service and Information Technology BuildingJanuary 29, 2015 10:40 am | News | Comments
Following 16 months of construction, the first phase of a modern, multi-functional building at Vetter’s Ravensburg Schuetzenstrasse site has been completed. Estimated to be fully operational by the beginning of 2016, the new facility will contain high-tech laboratories and workplaces for Vetter Development Service, as well as a highly secure data center and additional office space for a total area of 8,500 sqm.
Improved investigative site relationship use and effectiveness are top objectives in 2015 for pharmaceutical companies and contract research organizations, according to drug industry R&D executives participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development.
Pharmaceutical Product Development, (PPD) has completed an expansion of its clinical supplies facility in Athlone, Ireland, that will enable the company to double its packaging warehousing capabilities and quadruple its distribution services. Those increases are the result of PPD more than tripling the size of the facility as part of its long-term strategy to expand its global depot network.
Scientifically Adept - Platform Agnostic: Particle Sciences Positions Itself as a Bioavailability Tool for Most Dosage FormsJanuary 22, 2015 11:50 am | by Mike Auerbach, Editor In Chief | Articles | Comments
Particle Sciences, a drug development services company located in Bethlehem, Pennsylvania, has based its business model on being platform/technology agnostic. Bring them your drug development, formulation or dosage form problem and they will apply the right set of tools and technology to advance your project.
Catalent Expands Integrated Softgel Operations Through Coating and Packaging Investment In Eberbach, GermanyJanuary 22, 2015 10:44 am | News | Comments
Catalent Pharma Solutions will adding new coating and blister packaging equipment at its 360,000 sq ft, Eberbach, Germany softgel manufacturing facility, expanding the integrated softgel solutions available.
The Pharma & Biopharma Outsourcing Association (PBOA) today announced that Nelson Patterson, Vice President, Sales and Marketing at Baxter BioPharma Solutions, has been elected to its Board of Trustees, effective immediately. Mr. Patterson was elected after Baxter BioPharma Solutions joined the PBOA as a Sustaining Member.
Catalent Pharma Solutions and Mitsubishi Gas Chemical Company, Inc. (MGC), have entered into a partnership agreement to co-promote Catalent’s proprietary GPEx® technology in the Asian market.
AMRI has received a 10-year federal contract award from the NIH for drug development and manufacturing services. This NIH/National Institute of Neurological Disorders and Stroke award will support NIH's Drug Manufacturing and Formulation Program, which is a component of the Blueprint Neurotherapeutics Network. AMRI has supported the NIH BPN since 2011, providing chemistry services and discovery technologies.
Boehringer Ingelheim and Sanofi announced today that they enter into an alliance to extend Sanofi’s manufacturing capacity network for therapeutic monoclonal antibodies.
Catalent and Sanofi to Collaborate On Smartag™ Antibody-Drug Conjugate Technology With Sanofi’s Proprietary AntibodiesJanuary 15, 2015 8:07 am | News | Comments
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates (ADCs).
SGS Life Science Services today announced that its laboratory in Poitiers, France, has successfully completed a full analytical validation of the novel Meso Scale Discovery (MSD®) V-PLEX 10-plex Proinflammatory Panel I, for use with human plasma samples.
This novel technology uses lipid-like counter-ion salts to improve the solubility of drugs in lipid-based liquid, semi-solid and multiparticulate formulations. This technology adds to Capsugel Dosage Form Solutions’ growing suite of bioavailability enhancement technologies and capabilities.
AMRI will initially provide cGMP manufacture and analytical support for the registration of five product candidates. AMRI will be reimbursed for technology transfer activities, analytical development and manufacture of regulatory submission batches. In addition, AMRI is eligible to receive additional payments for achieving product delivery milestones.
Aptuit has divested its aseptic clinical manufacturing site in Glasgow, UK to Albany Molecular Research, Inc., and has entered into a definitive agreement with AMRI to acquire the West Lafayette, Indiana solid-state chemistry business for a total consideration of $60 million.
Pharmaceutical Product Development and Shin Nippon Biomedical Labs have formed a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.
Bayer HealthCare and Cardinal Health have signed a 15-year agreement for the contract manufacturing of Xofigo. As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo.
The non-profit New England CRO/CMO Council is open to CROs and CMOs operating in and around Boston, the nation's largest life sciences cluster. The Council is designed to market the cluster and to provide the broader BioPharma community with a means of accessing local CRO’s, CMOs and other suppliers to meet their current and future outsourcing requirements.
Pharmaceutical Product Development and ERT today announced a strategic partnership to facilitate delivery of ERT’s comprehensive solutions for patient safety and efficacy endpoint data collection to help biopharmaceutical clients conduct clinical trials in a more efficient and cost-effective manner.
Scilabs Nutraceuticals Inc., a contract manufacturer of nutraceuticals based in Irvine, California, has commented on the recent consent decree that it entered into with the FDA, in which the company agreed to suspend nutraceutical manufacturing operations.
Vetter has announced that its U.S. early-stage development site located at the Illinois Science + Technology Park in suburban Chicago, has completed the next step of its expansion with the addition of a third cleanroom. Clinical syringe projects are now being accepted at the facility, which can handle preclinical through phase II projects.
Avid Bioservices, the contract manufacturing subsidiary of Peregrine Pharmaceuticals, has initiated an expansion of its biomanufacturing capacity. The new production facility will more than double Avid Bioservices' current manufacturing capacity in a state-of-the-art facility design.
Meda, a Recipharm’s customer, announced that they will transfer supply of their mainly Swedish penicillin products and manufacture offshore with other suppliers. The manufacturing contract with Recipharm Strängnäs will therefore be terminated as of December 31, 2015.
Catalent Pharma Solutions has reached an exclusive development and licensing agreement with Swiss-based development-stage biopharmaceutical company SELLAS Life Sciences Group, to support the development and therapeutic reprofiling of zolpidem using Catalent’s OSDrC® OptiDose™ drug delivery technology.
Noble Life Sciences, a provider of preclinical drug development services, has announced the acquisition of Spring Valley Laboratories, a full service, GLP-compliant, preclinical contract research organization for the development of drugs, vaccines, and medical devices.
- Page 1